Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moderna Inc MRNA

Healthcare Biotechnology
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular... see more

Recent & Breaking News (NDAQ:MRNA)

Moderna to Present at Upcoming Conferences in December 2024

Accesswire 3 hours ago

Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year

Accesswire 13 days ago

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

PR Newswire November 8, 2024

Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older

Accesswire November 8, 2024

Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

Accesswire November 7, 2024

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

PR Newswire November 5, 2024

Shareholder Notice to Long-Term Shareholders of Moderna, Inc. (MRNA)

Newsfile November 3, 2024

Moderna to Present at Upcoming Conferences in November 2024

Accesswire October 31, 2024

Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)

Business Wire October 28, 2024

Moderna Named a Top Employer by Science for Tenth Consecutive Year

Accesswire October 24, 2024

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

PR Newswire October 23, 2024

Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

Accesswire October 17, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 8, 2024 in Moderna Lawsuit - MRNA

Accesswire October 8, 2024

Investors Who Lost Money on Moderna, Inc. (MRNA) Should Contact Levi & Korsinsky About Pending Class Action - MRNA

Accesswire October 8, 2024

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna

Newsfile October 8, 2024

MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Business Wire October 8, 2024

Moderna, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRNA

Accesswire October 8, 2024

FINAL MRNA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Moderna, Inc. Investors to Join the Class Action Lawsuit!

Accesswire October 8, 2024

Moderna, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your Rights - MRNA

PR Newswire October 8, 2024

Investors in Moderna, Inc. Should Contact Levi & Korsinsky Before October 8, 2024 to Discuss Your Rights -- MRNA

Accesswire October 7, 2024